Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 7/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841596 | 0.83 | BTK (0.47) | EPHX2EPHX1CA1CA2KMT2A | |
| SCHEMBL26478102 | 0.83 | EPHX1 (0.58) | EPHX2EPHX1ALDH1A1CA12CA1 | |
| SCHEMBL21841587 | 0.81 | RECQL (0.56) | EPHX2EPHX1RECQLSTSPTPN2 | |
| SCHEMBL21841521 | 0.81 | HSD11B1 (0.45) | EPHX1CA1CA2RECQLHPGD | |
| SCHEMBL26131308 | 0.81 | EPHX1 (0.74) | EPHX2EPHX1ALDH1A1RECQLPTPN2 | |
| SCHEMBL1514783 | 0.80 | EPHX1 (0.64) | EPHX2EPHX1ALDH1A1RECQLSTS | |
| SCHEMBL1623238 | 0.78 | EPHX1 (0.57) | EPHX2EPHX1ALDH1A1PTPN2PTPN1 | |
| SCHEMBL1437840 | 0.78 | EPHX1 (0.74) | EPHX2EPHX1ALDH1A1RECQLPTPN2 | |
| SCHEMBL4922317 | 0.78 | EPHX1 (0.57) | EPHX2EPHX1ALDH1A1PTPN2PTPN1 | |
| SCHEMBL1623236 | 0.78 | EPHX1 (0.57) | EPHX2EPHX1ALDH1A1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | EPHX2 1657/4885EPHX1 1134/4885ALDH1A1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.